Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” This research paper was published, in the 29 March 2012 issue of the journal “Nature” [One of the best research journals in Science […]

Molecular therapy for TIIDM and obesity-associated metabolic deficits: D-3-hydroxybutyrate (D3HB)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 6/February/2018, 6.45 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” This research paper, was published in the 8 March 2017 issue of the journal “Nature” [One of the best research journals […]

Life-extension therapy: Lansoprazole, a drug used in the treatment of stomach and duodenal ulcers,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 6/February/2017, 6.30 pm

What they say? A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published, in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ), by Prof Dominic J. Withers, Dr. Selman C and others. What we say:  On the foundation of […]

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: D-3-Hydroxybutyrate (3DHB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 5/February/2018, 11.06 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” This research paper was published, in the 8 March 2017 issue of the journal “Nature” [One of the best research journals in General Science with an I.F […]

Lifespan extension therapy: Lanzoprazole[Brand name: Prevacid], a medication that decreases the secretion of acid from stomach, increases life span via up-regulation of its target gene BubR1, 5/February/2018, 10.46 pm

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the […]

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 5/February/2018, 12.07 am

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge, Massachusetts, USA shows that “Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.” This study was published, in the 5 July […]